DVA

Kidney dialysis is not a market anyone chooses to enter as a patient. It is a market defined by medical necessity, chronic recurrence, and a patient population that, by definition, cannot stop consuming the service. In the United States, roughly 550,000 patients depend on regular dialysis treatments, with end-stage renal disease (ESRD) prevalence growing at approximately 1% to 2% per year. This is the structural foundation upon which DaVita Inc. has built one of the most unusual franchises in American healthcare: a company whose demand curve is biologically mandated and whose competitive position is reinforced by the sheer capital intensity and regulatory complexity of building and operating dialysis clinics at scale.

DaVita operates approximately 2,700 outpatient dialysis centers across the United States and treats roughly 200,000 patients, making it, alongside Fresenius Medical Care, one of only two companies that together control roughly 70% of the U.S. dialysis market. The duopoly is not accidental. It is the product of decades of consolidation, regulatory barriers to entry, and a business model where geographic density and payer negotiation leverage compound over time. Smaller operators have not merely struggled to compete; they have been absorbed. The independent dialysis center, once a common feature of the renal care landscape, is increasingly an artifact.

The central analytical question for DaVita is not whether the moat exists. It clearly does. The question is whether the moat is expanding or contracting, and the answer depends on which direction one looks. From the ground up, DaVita's clinic network and operating discipline are as formidable as ever. From the top down, the regulatory and reimbursement environment is shifting in ways that could either entrench DaVita's dominance further or gradually erode its pricing power. The company is simultaneously the most structurally defended player in its core market and the most exposed to a single, politically sensitive payer: the U.S. federal government, through Medicare. This tension, between operational strength and regulatory dependency, defines DaVita's investment case in 2026.

Here is the observation that standard financial summaries miss: DaVita's true competitive advantage is not its scale or its brand. It is the fact that building a competing national dialysis network would take a decade and billions of dollars, and no rational economic actor would attempt it because the reimbursement environment makes the return on that investment deeply uncertain. DaVita's moat is protected not by the attractiveness of the market, but by its unattractiveness to new entrants. The barriers are made of regulatory concrete, not gold.